Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 1.53 g/t Au over 191.3m in infill drilling at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News CAMP4 Therapeutics Corporation CAMP

Healthcare Biotechnology
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics... see more

Recent & Breaking News (NDAQ:CAMP)

    CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire November 14, 2025

    CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

    GlobeNewswire November 6, 2025

    CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

    GlobeNewswire October 1, 2025

    CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

    GlobeNewswire September 10, 2025

    CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

    GlobeNewswire August 14, 2025

    CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

    GlobeNewswire May 16, 2025

    CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

    GlobeNewswire May 13, 2025

    CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

    GlobeNewswire April 28, 2025

    CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

    GlobeNewswire March 27, 2025

    CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

    GlobeNewswire March 18, 2025

    CAMP4 to Participate in Upcoming Investor Conferences

    GlobeNewswire February 6, 2025

    CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    GlobeNewswire January 13, 2025

    CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

    GlobeNewswire January 7, 2025

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    GlobeNewswire December 10, 2024

    CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

    GlobeNewswire December 2, 2024

    CAMP4 Reports Third Quarter 2024 Financial Results

    GlobeNewswire November 21, 2024